Literature DB >> 9764429

Assessment of myocardial glutamate requirements early after coronary artery bypass surgery.

I Vanhanen1, R Svedjeholm, E Håkanson, P O Joachimsson, L Jorfeldt, L Nilsson, F Vanky.   

Abstract

Glutamate is an important substrate for the intermediary metabolism of the heart, particularly in association with ischemia. Early after coronary artery bypass surgery (CABG) myocardial uptake of glutamate seems to be limited by substrate availability (arterial levels). However, glutamate is not an innocuous substrate. As arterial levels of glutamate are important both for myocardial uptake and adverse effects, an attempt was made to determine a minimum dose of glutamate sufficient to supply the needs of the heart after CABG. Ten patients received and infusion of 220-240 ml of 0.1 M L-glutamic acid solution at varying rates during two 30-min periods, starting 2 h after uncomplicated elective CABG. Intravenous glutamate infusion caused a dose-dependent linear increase in arterial glutamate and an increased myocardial uptake of glutamate. However, myocardial uptake of glutamate correlated with arterial levels only at lower infusion rates. Although maximal peak uptake in individual patients (6.6 +/- 1.1 mumol/min) occurred at an average increase of arterial whole blood glutamate of 172 +/- 34 mumol/L, the greatest impact on myocardial glutamate uptake was achieved by increasing arterial whole blood glutamate by less than 100 mumol/L. This implies that an infusion rate of 30-40 mg glutamate/kg BW/h could suffice to achieve a maximal or near maximal myocardial glutamate uptake in most patients after CABG. The adequacy of this dosage remains to be confirmed in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764429     DOI: 10.1080/14017439850140102

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  3 in total

1.  Post hoc analysis of the glutamics-trial: intravenous glutamate infusion and use of inotropic drugs after cabg.

Authors:  Mårten Vidlund; Bashir Tajik; Erik Håkanson; Örjan Friberg; Jonas Holm; Farkas Vanky; Rolf Svedjeholm
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

2.  Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.

Authors:  Jonas Holm; Gabriele Ferrari; Anders Holmgren; Farkas Vanky; Örjan Friberg; Mårten Vidlund; Rolf Svedjeholm
Journal:  PLoS Med       Date:  2022-05-09       Impact factor: 11.613

3.  The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.

Authors:  Huiqi Jiang; Jonas Holm; Mårten Vidlund; Farkas Vanky; Örjan Friberg; Yanqi Yang; Rolf Svedjeholm
Journal:  J Transl Med       Date:  2020-05-11       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.